TrialHuman vaccines & immunotherapeutics2014

Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.

Eva Rossmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.